DK1301614T3 - Codon-optimerede papillomavirus-sekvenser - Google Patents

Codon-optimerede papillomavirus-sekvenser

Info

Publication number
DK1301614T3
DK1301614T3 DK01953199T DK01953199T DK1301614T3 DK 1301614 T3 DK1301614 T3 DK 1301614T3 DK 01953199 T DK01953199 T DK 01953199T DK 01953199 T DK01953199 T DK 01953199T DK 1301614 T3 DK1301614 T3 DK 1301614T3
Authority
DK
Denmark
Prior art keywords
codon
optimized
amino acid
sequences
relates
Prior art date
Application number
DK01953199T
Other languages
Danish (da)
English (en)
Inventor
Sarah Marina Walcott
Peter F Ertl
Gerald W Gough
Christopher J Ring
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0017990.3A external-priority patent/GB0017990D0/en
Priority claimed from GB0025802A external-priority patent/GB0025802D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1301614T3 publication Critical patent/DK1301614T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK01953199T 2000-07-21 2001-07-20 Codon-optimerede papillomavirus-sekvenser DK1301614T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0017990.3A GB0017990D0 (en) 2000-07-21 2000-07-21 Papilloma virus sequences
GB0025802A GB0025802D0 (en) 2000-10-20 2000-10-20 Papilloma virus sequences
PCT/GB2001/003290 WO2002008435A1 (fr) 2000-07-21 2001-07-20 Sequences de papillomavirus a codon optimise

Publications (1)

Publication Number Publication Date
DK1301614T3 true DK1301614T3 (da) 2007-04-02

Family

ID=26244703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01953199T DK1301614T3 (da) 2000-07-21 2001-07-20 Codon-optimerede papillomavirus-sekvenser

Country Status (22)

Country Link
EP (1) EP1301614B1 (fr)
JP (1) JP2004504057A (fr)
KR (1) KR100874552B1 (fr)
CN (1) CN1262665C (fr)
AT (1) ATE346947T1 (fr)
AU (2) AU7569501A (fr)
BR (1) BR0112637A (fr)
CA (1) CA2416488A1 (fr)
CY (1) CY1106334T1 (fr)
CZ (1) CZ2003180A3 (fr)
DE (1) DE60124918T2 (fr)
DK (1) DK1301614T3 (fr)
ES (1) ES2277605T3 (fr)
HK (1) HK1056195B (fr)
HU (1) HUP0300745A3 (fr)
IL (1) IL154009A0 (fr)
MX (1) MXPA03000554A (fr)
NO (1) NO20030219L (fr)
NZ (1) NZ523683A (fr)
PL (1) PL365385A1 (fr)
PT (1) PT1301614E (fr)
WO (1) WO2002008435A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
CA2457890A1 (fr) * 2001-08-23 2003-03-06 Merck & Co., Inc. Vaccin mettant en oeuvre des proteines e du virus du papillome administrees par vecteur viral
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
KR101080628B1 (ko) 2003-03-24 2011-11-08 머크 샤프 앤드 돔 코포레이션 효모에서 ｈｐｖ 31 ｌ1의 최적 발현
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
MY148656A (en) 2004-03-24 2013-05-15 Merck Sharp & Dohme Optimized expression of hpv 52 l1 in yeast.
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
WO2008133663A2 (fr) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Compositions immunogènes à codons modifiés et procédés d'utilisation
GB0700914D0 (en) * 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
KR101621100B1 (ko) 2007-03-30 2016-05-13 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 백신에 유용한 약독화 바이러스
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
WO2012019168A2 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucléiques modifiés et leurs procédés d'utilisation
EP2625189B1 (fr) 2010-10-01 2018-06-27 ModernaTX, Inc. Synthèse d'acides nucléiques et méthodes d'utilisation associées
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (fr) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Nucleoside, nucleotide, et compositions d'acide nucleique modifies
WO2013151665A2 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de protéines associées à une maladie humaine
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
WO2015062738A1 (fr) 2013-11-01 2015-05-07 Curevac Gmbh Arn modifié à propriétés immunostimulantes réduites
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
WO2017070624A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre des maladies tropicales
WO2017070601A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv)
CN108289913A (zh) 2015-10-30 2018-07-17 儿童国家医疗中心 从未致敏t细胞群体产生hpv抗原特异性t细胞
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018107088A2 (fr) 2016-12-08 2018-06-14 Modernatx, Inc. Vaccins à acide nucléique contre des virus respiratoires
WO2018170256A1 (fr) 2017-03-15 2018-09-20 Modernatx, Inc. Vaccin contre le virus de l'herpès simplex
WO2018170270A1 (fr) 2017-03-15 2018-09-20 Modernatx, Inc. Vaccin contre le virus varicelle-zona
EP3595713A4 (fr) 2017-03-15 2021-01-13 ModernaTX, Inc. Vaccin contre le virus respiratoire syncytial
WO2018170245A1 (fr) 2017-03-15 2018-09-20 Modernatx, Inc. Vaccin à large spectre contre le virus de la grippe
WO2019055807A1 (fr) 2017-09-14 2019-03-21 Modernatx, Inc. Vaccins à arn contre le virus zika
EP3746090A4 (fr) 2018-01-29 2021-11-17 ModernaTX, Inc. Vaccins à base d'arn contre le vrs
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464936A (en) * 1990-12-21 1995-11-07 Cetus Oncology Corporation Compositions for identification of papillomavirus replication inhibitors
DE4123760C2 (de) * 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
EE9900343A (et) * 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
SI1108035T1 (sl) * 1998-09-04 2007-12-31 Sanofi Pasteur Ltd Zdravljenje raka materničnega vratu
EP1212358B1 (fr) * 1999-08-25 2004-12-15 Merck & Co., Inc. Genes synthetiques humains du virus de papillome

Also Published As

Publication number Publication date
CA2416488A1 (fr) 2002-01-31
HK1056195A1 (en) 2004-02-06
HUP0300745A2 (hu) 2003-08-28
IL154009A0 (en) 2003-07-31
AU7569501A (en) 2002-02-05
EP1301614A1 (fr) 2003-04-16
CN1262665C (zh) 2006-07-05
CY1106334T1 (el) 2011-10-12
AU2001275695B9 (en) 2005-05-26
PL365385A1 (en) 2005-01-10
KR20030074586A (ko) 2003-09-19
DE60124918T2 (de) 2007-08-02
PT1301614E (pt) 2007-02-28
KR100874552B1 (ko) 2008-12-16
ES2277605T3 (es) 2007-07-16
ATE346947T1 (de) 2006-12-15
CN1462309A (zh) 2003-12-17
AU2001275695B2 (en) 2005-01-27
MXPA03000554A (es) 2004-12-13
BR0112637A (pt) 2003-06-10
NO20030219D0 (no) 2003-01-16
WO2002008435A1 (fr) 2002-01-31
CZ2003180A3 (cs) 2003-08-13
EP1301614B1 (fr) 2006-11-29
JP2004504057A (ja) 2004-02-12
NZ523683A (en) 2004-08-27
NO20030219L (no) 2003-03-20
HK1056195B (en) 2007-06-22
DE60124918D1 (de) 2007-01-11
WO2002008435A8 (fr) 2002-04-04
HUP0300745A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
DK1301614T3 (da) Codon-optimerede papillomavirus-sekvenser
DE602004023725D1 (de) Muteine von tränen-lipocalin
HUP0401124A2 (hu) VII koagulációs faktor származékok
MXPA04003796A (es) Tioacetamidas sustituidas.
MXPA02011288A (es) Tioacetamidas substituidas.
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
HUP0100526A2 (hu) HPV-antigén elleni készítmények, alkalmazásaik és eljárások előállításukra
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
WO2003020889A3 (fr) Procedes de maturation de cellules dendritiques plasmocytoides au moyen de molecules modifiant les reponses immunitaires
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
TW200407425A (en) Human coagulation factor VII polypeptides
TW200502246A (en) Vaccine
EP1613345A4 (fr) Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
EA201000386A1 (ru) Нетоксичные для нервной ткани плазминоген-активирующие факторы для лечения инсульта
EP1149917A3 (fr) Vecteurs derivés du virus Hépatitis B pour la thérapie gènique
WO2005002511A3 (fr) Anticorps recombines, compositions et leurs methodes de fabrication et d'utilisation
ATE408013T1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
UA84831C2 (ru) Производные фактора коагуляции vii
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
IL169256A0 (en) Metalloprotease proteins
NO20062316L (no) Nye CXCL8 antagonister
WO2003091393A3 (fr) Proteines humaines isolees presentant une homologie elevee avec des proteines humaines pathologiques, molecules d'acides nucleiques codant ces proteines humaines, et utilisations associees